HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega-3 Use Grows Despite Doubts, Herbals Rise Above NY Controversy

This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition’s 16th annual survey shows questions raised by researchers, state officials and media about the safety and efficacy of some supplement ingredients do not appear to slowing users’ interest in the products.

You may also be interested in...



AREDS-Inspired Study Challenges Omega-3 Cognitive Benefit Claims

Omega-3 supplementation had no impact on cognitive function in a five-year assessment of elderly people participating in AREDS2 research, say NIH researchers. But they add in the JAMA study that longer-term use of omega-3s could result in a different outcome.

Omega-3 Questions Could Pull Plug On Sales Growth

Pharma firms’ introduction and wide promotion of Rx drugs containing EPA or DHA acids and aimed at improving cardiovascular health were expected to boost omega-3 supplement sales, but negative research results reported over the past year could diminish consumers’ regard for the nutrients’ benefits.

PCPC Working To Ensure State EPR Programs Are ‘Least Onerous As Possible’

The Personal Care Products Council is engaging on state legislation for extended producer responsibility programs, which impose the cost of recycling plastic materials on manufacturers. Emerging bills to prohibit use of the ‘chasing arrows’ recycling symbol on consumer packaging also have the trade group’s attention.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS123527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel